| |
Total
|
pCR (N = 25)
|
No pCR (N = 93)
|
P value
|
|---|
|
N = 118
|
n
|
%a
|
n
|
%a
|
|---|
|
Tumor size
|
|
T0-T1
|
5
|
1
|
20.0
|
4
|
80.0
| |
|
T2
|
60
|
16
|
26.7
|
44
|
73.3
| |
|
T3
|
24
|
3
|
12.5
|
21
|
87.5
| |
|
T4
|
27
|
4
|
14.8
|
23
|
85.2
|
NS†
|
|
NA
|
2
|
1
| |
1
| | |
|
Histopronostic grade
|
|
SBRI–SBRII
|
61
|
9
|
14.8
|
52
|
85.2
| |
|
SBRIII
|
43
|
16
|
37.2
|
27
|
62.8
|
0.009*
|
|
NA
|
14
|
0
| |
14
| | |
|
Nodal status
|
|
Positive
|
63
|
12
|
19.1
|
51
|
80.9
| |
|
Negative
|
53
|
12
|
22.6
|
41
|
77.4
|
NS†
|
|
NA
|
2
|
1
| |
1
| | |
|
KI67
|
|
Positive
|
42
|
12
|
28.6
|
30
|
71.4
| |
|
Negative
|
6
|
0
|
0.0
|
6
|
100.0
|
NS†
|
|
NA
|
70
|
13
| |
57
| | |
|
Hormone receptor status
|
|
RH
|
|
Positiveb
|
77
|
12
|
15.6
|
65
|
84.4
| |
|
Negativec
|
39
|
13
|
33.3
|
26
|
66.7
|
0.003*
|
|
NA
|
2
|
0
| |
2
| | |
|
RE
|
|
Positive
|
74
|
10
|
13.5
|
64
|
86.5
| |
|
Negative
|
42
|
15
|
35.7
|
27
|
64.3
|
0.005*
|
|
NA
|
2
|
0
| |
2
| | |
|
RP
|
|
Positive
|
57
|
10
|
17.5
|
47
|
82.5
| |
|
Negative
|
58
|
15
|
25.9
|
43
|
74.1
|
NS*
|
|
NA
|
3
|
0
| |
3
| | |
|
Triple negative
|
|
Yes
|
32
|
13
|
40.6
|
19
|
59.4
| |
|
No
|
75
|
12
|
16.0
|
63
|
84.0
|
0.006*
|
|
NA
|
11
|
0
| |
11
| | |
-
NA not applicable, pCR pathological complete response.
- * Khi-2 test.
-
† Fisher exact test.
-
‡ Wilcoxon Mann–Whitney test.
-
aPercentages of evaluable patients.
-
bEstrogen receptor or progesterone receptor positive.
-
cEstrogen receptor and progesterone receptor negative.
